Subcutaneous injection of hydrogen gas is a novel effective treatment for type 2 diabetes.
Xiaolong Zhang, Jiaming Liu, Keke Jin, Haifeng Xu, Chuang Wang, Zhuang Zhang, Mimi Kong, Zhengzheng Zhang, Qingyi Wang, Fangyan Wang · Journal of diabetes investigation · 2018
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In mice, levels of LDL and TG, but not total cholesterol, were significantly attenuated, whereas the level of high‐density lipoprotein was increased after H₂ treatment in the SAH group (** P < 0.01; Figure 2 ). The bodyweight of H₂ -treated mice did not change over the course of the experiment. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in mice. Levels of LDL and TG, but not total cholesterol, were significantly attenuated, whereas the level of high‐density lipoprotein was increased after H₂ treatment in the SAH group (** P < 0.01; Figure 2 ).
What the Researchers Studied
The researchers studied mice. The study used a preclinical animal experiment. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Mice were divided into three groups: mice without diabetes induction (normal control [NC], n = 8); diabetic mice receiving subcutaneous injection of air (DM; n = 15); diabetic mice receiving subcutaneous injections of H₂ (SAH; n = 15). The SAH group was injected subcutaneously with H₂ at a dose of 1 mL/mouse/week for 4 weeks. Figure 1 Subcutaneous administration of hydrogen gas (H₂ ) suppressed hyperglycemia in mice with diabetes mellitus ( DM ) induced by a high‐fat diet and a low dose of streptozotocin. Levels of LDL and TG, but not total cholesterol, were significantly attenuated, whereas the level of high‐density lipoprotein was increased after H₂ treatment in the SAH group (** P < 0.01; Figure 2 ).
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was mice. The study used a preclinical animal experiment.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.